Skip to main content
Phase 3 study to be initiated for second long-acting injectable antipsychotic using MedinCell’s technology
August 29, 2022
MedinCell: inclusion of first participants in new Covid-19 prophylaxis clinical trial SAIVE
March 28, 2022
MedinCell provides an update on its product portfolio, following the FDA Acceptance of New Drug Application for the product mdc-IRM
September 1, 2021
MedinCell’s Long-Acting Injectable to fight Malaria ready to enter Regulatory Development
June 14, 2021
Clinical trial conducted by MedinCell confirms the safety of continuous administration of ivermectin
April 19, 2021
MedinCell: mdc-CWM clinical phase 3 will start in 2021
March 25, 2021
Covid-19: MedinCell publishes an extensive Ivermectin Safety Expert Analysis
March 5, 2021
MedinCell announces three new products entering regulatory development
February 2, 2021
Covid-19: MedinCell presents positive first results from the clinical trial aiming at validating the safety of continuous administration of Ivermectin
December 17, 2020
MedinCell initiates the first clinical trial of its Covid-19 prevention program
September 29, 2020
